Dr Woods said, “The MedTech Innovator Acceleartor programme has been hugely valuable to Newrotex. Working with so many expert entrepreneurs, clinical experts and large strategics to refine our value proposition, strategy and market value has been invaluable. As well as making friends with so many incredible entrepreneurs! It was a great honour for Newrotex to have been selected as one of the top 5 companies from the MedTech Innovator 2023 cohort – from an initial 1,150 companies across the world who applied this year – it really shows the value of what we’re trying to achieve for patients. Congratulations to winners StrokeDx and to the other incredible companies who were included in the Finals IFPx, Fingy3D, and Neurava Inc.